Black Diamond Therapeutics (BDTX) Change in Account Payables (2019 - 2026)
Black Diamond Therapeutics (BDTX) posted Change in Account Payables of $2.4 million for Q1 2026, up 703.54% on a QoQ basis from -$396000.0 in Q4 2025, and up 273.31% year-over-year from $640211.7 in Q1 2025.
Black Diamond Therapeutics (BDTX) Change in Account Payables (2019 - 2026) Analysis & Trends
Black Diamond Therapeutics' Change in Account Payables history runs 8 years deep, the most recent figure standing at $2.4 million for Q1 2026.
- Quarterly Change in Account Payables rose 273.31% year-over-year to $2.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $341000.0 (down 76.19% YoY) and the FY2025 annual result came in at -$3.4 million, down 303.68% from the prior year.
- Change in Account Payables was $2.4 million for Q1 2026 at Black Diamond Therapeutics, up from -$396000.0 in the prior quarter.
- Across five years, Change in Account Payables topped out at $3.5 million in Q3 2022 and bottomed at -$3.9 million in Q4 2022.
- A 5-year average of -$58117.6 and a median of -$343000.0 in 2023 frame the typical range for Change in Account Payables.
- Peak annual rise in Change in Account Payables reached 463.38% in 2022, while the deepest fall reached 459.51% in 2022.
- Black Diamond Therapeutics' Change in Account Payables stood at -$3.9 million in 2022, then soared by 141.98% to $1.6 million in 2023, then climbed by 24.91% to $2.0 million in 2024, then sank by 119.45% to -$396000.0 in 2025, then jumped by 703.54% to $2.4 million in 2026.
- Business Quant data shows BDTX's Change in Account Payables at $2.4 million in Q1 2026, -$396000.0 in Q4 2025, and $204000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Account Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -42.19 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 35.60 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 16.86 Mn |
| 10 | Black Diamond Therapeutics | 99.59 Mn | -18.67 Mn | - | 2.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.39 Mn |
| Mar 31, 2026 | 2.39 Mn |
| Dec 31, 2025 | -396,000.00 |
| Dec 31, 2025 | -396,000.00 |
| Sep 30, 2025 | 204,000.00 |
| Sep 30, 2025 | 204,000.00 |
| Jun 30, 2025 | -1.86 Mn |
| Jun 30, 2025 | -1.86 Mn |
| Mar 31, 2025 | -1.38 Mn |
| Mar 31, 2025 | -1.38 Mn |
| Dec 31, 2024 | 2.04 Mn |
| Dec 31, 2024 | 2.04 Mn |
| Sep 30, 2024 | 1.21 Mn |
| Sep 30, 2024 | 1.21 Mn |
| Jun 30, 2024 | -433,000.00 |
| Jun 30, 2024 | -433,000.00 |
| Mar 31, 2024 | -1.13 Mn |
| Mar 31, 2024 | -1.13 Mn |
| Dec 31, 2023 | 1.63 Mn |
| Dec 31, 2023 | 1.63 Mn |